JP2024527180A - 細胞免疫療法の使用 - Google Patents
細胞免疫療法の使用 Download PDFInfo
- Publication number
- JP2024527180A JP2024527180A JP2023562228A JP2023562228A JP2024527180A JP 2024527180 A JP2024527180 A JP 2024527180A JP 2023562228 A JP2023562228 A JP 2023562228A JP 2023562228 A JP2023562228 A JP 2023562228A JP 2024527180 A JP2024527180 A JP 2024527180A
- Authority
- JP
- Japan
- Prior art keywords
- cells
- seq
- cell
- patient
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4202—Receptors, cell surface antigens or cell surface determinants
- A61K40/421—Immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/31—Chimeric antigen receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4202—Receptors, cell surface antigens or cell surface determinants
- A61K40/4214—Receptors for cytokines
- A61K40/4215—Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR], CD30
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4254—Adhesion molecules, e.g. NRCAM, EpCAM or cadherins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4261—Proteoglycans, e.g. glypican, brevican or CSPG4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70521—CD28, CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
- A61K2239/51—Stomach
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
- A61K2239/52—Intestine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
- A61K2239/59—Reproductive system, e.g. uterus, ovaries, cervix or testes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110377518 | 2021-04-08 | ||
| CN202110377518.7 | 2021-04-08 | ||
| PCT/CN2022/085921 WO2022214089A1 (zh) | 2021-04-08 | 2022-04-08 | 细胞免疫治疗的应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024527180A true JP2024527180A (ja) | 2024-07-22 |
| JP2024527180A5 JP2024527180A5 (cg-RX-API-DMAC7.html) | 2025-03-25 |
Family
ID=83545188
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023562228A Pending JP2024527180A (ja) | 2021-04-08 | 2022-04-08 | 細胞免疫療法の使用 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20240181055A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4321533A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024527180A (cg-RX-API-DMAC7.html) |
| CN (1) | CN117545771A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022214089A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117430707B (zh) * | 2023-10-25 | 2024-04-19 | 重庆天科雅生物科技有限公司 | 一种cik细胞的制备方法及其在治疗癌症中的用途 |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2018508215A (ja) * | 2015-03-05 | 2018-03-29 | ユーシーエル ビジネス ピーエルシー | Cd19結合ドメインを含むキメラ抗原レセプター(car) |
| JP2019515913A (ja) * | 2016-04-22 | 2019-06-13 | 科済生物医薬(上海)有限公司Carsgen Therapeutics Limited | 細胞免疫療法の組成物および方法 |
| WO2019170147A1 (zh) * | 2018-03-09 | 2019-09-12 | 科济生物医药(上海)有限公司 | 用于治疗肿瘤的方法和组合物 |
| JP2019531084A (ja) * | 2016-07-08 | 2019-10-31 | カースゲン セラピューティクス カンパニー リミテッドCarsgen Therapeutics Co., Ltd. | 抗クローディンタンパク質18a2の抗体及びその応用 |
| WO2020143631A1 (zh) * | 2019-01-07 | 2020-07-16 | 科济生物医药(上海)有限公司 | 细胞免疫治疗的组合 |
| CN112062864A (zh) * | 2020-09-18 | 2020-12-11 | 樊克兴 | 靶向bcma肿瘤抗原受体修饰t细胞的制备方法和应用 |
Family Cites Families (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE199392T1 (de) | 1992-12-04 | 2001-03-15 | Medical Res Council | Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung |
| CN104087607B (zh) | 2013-04-01 | 2017-06-20 | 科济生物医药(上海)有限公司 | 编码嵌合抗原受体蛋白的核酸及表达嵌合抗原受体蛋白的t淋巴细胞 |
| CN104140974B (zh) | 2013-05-08 | 2017-09-29 | 科济生物医药(上海)有限公司 | 编码gpc‑3嵌合抗原受体蛋白的核酸及表达gpc‑3嵌合抗原受体蛋白的t淋巴细胞 |
| US9209965B2 (en) | 2014-01-14 | 2015-12-08 | Microsemi Semiconductor Ulc | Network interface with clock recovery module on line card |
| JP6682509B2 (ja) | 2014-05-14 | 2020-04-15 | カースゲン セラピューティクス リミテッドCarsgen Therapeutics Limited | キメラ抗原受容体タンパク質をコードする核酸およびキメラ抗原受容体タンパク質を発現するtリンパ球 |
| CN105194661B (zh) | 2014-06-26 | 2019-05-03 | 科济生物医药(上海)有限公司 | 时空可调性抑制病理性靶细胞的系统 |
| CN120329449A (zh) | 2014-07-17 | 2025-07-18 | 恺兴生命科技(上海)有限公司 | 靶向cld18a2的t淋巴细胞及其制备方法和应用 |
| US10093746B2 (en) | 2014-09-04 | 2018-10-09 | The Trustees Of The University Of Pennsylvania | Glypican-3 antibody and uses thereof |
| ES2851123T1 (es) | 2014-09-26 | 2021-09-03 | Baylor College Medicine | Receptores quiméricos de antígeno específicos de glipicano-3 para inmunoterapia adoptiva |
| CN105713881B (zh) | 2014-12-04 | 2019-12-06 | 科济生物医药(上海)有限公司 | 双靶向gpc3和asgpr1的转基因免疫效应细胞及其应用 |
| CN106146666B (zh) | 2015-03-26 | 2019-09-06 | 科济生物医药(上海)有限公司 | 靶向cldn6的免疫效应细胞及其制备方法和应用 |
| AU2016304060B2 (en) | 2015-08-03 | 2022-09-29 | Crage Medical Co., Limited | Antibody against glypican-3 and application thereof |
| CN106467573B (zh) | 2015-08-21 | 2021-05-25 | 佧珐药业有限公司 | 抗间皮素全人抗体以及靶向间皮素的免疫效应细胞 |
| CN106519037B (zh) | 2015-09-11 | 2019-07-23 | 科济生物医药(上海)有限公司 | 可活化的嵌合受体 |
| CN109824778B (zh) | 2015-09-18 | 2022-07-19 | 上海科济制药有限公司 | 抗cd19全人抗体以及靶向cd19的免疫效应细胞 |
| CN105331585A (zh) | 2015-11-13 | 2016-02-17 | 科济生物医药(上海)有限公司 | 携带pd-l1阻断剂的嵌合抗原受体修饰的免疫效应细胞 |
| CN118165113B (zh) | 2016-04-26 | 2025-10-28 | 恺兴生命科技(上海)有限公司 | 一种改善免疫应答细胞功能的方法 |
| US11427633B2 (en) | 2016-12-13 | 2022-08-30 | Crage Medical Co., Limited | Anti-CD19 humanized antibody and immune effector cell targeting cd 19 |
| EP3572427B1 (en) | 2017-01-23 | 2025-06-25 | CRAGE medical Co., Limited | Bcma-targeting antibody and use thereof |
| CN108456250B (zh) | 2017-02-17 | 2025-11-28 | 恺兴生命科技(上海)有限公司 | 靶向il-13ra2的抗体及其应用 |
| WO2018149358A1 (zh) | 2017-02-17 | 2018-08-23 | 科济生物医药(上海)有限公司 | 靶向il-13ra2的抗体及其应用 |
| EP3585817A4 (en) * | 2017-02-22 | 2020-12-02 | Aleta Biotherapeutics Inc. | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER |
| CN108853144A (zh) | 2017-05-16 | 2018-11-23 | 科济生物医药(上海)有限公司 | Toll样受体激动剂与免疫效应细胞的联用 |
| CN108866003A (zh) | 2017-05-16 | 2018-11-23 | 科济生物医药(上海)有限公司 | 基因工程化的细胞及应用 |
| KR102412805B1 (ko) | 2017-05-31 | 2022-06-27 | 크라제 메디컬 씨오 리미티드 | 세포 면역 요법을 위한 조성물 및 방법 |
| CN109385403B (zh) | 2017-08-04 | 2024-03-08 | 恺兴生命科技(上海)有限公司 | 靶向gpc3的car nk细胞 |
| CN109385400A (zh) | 2017-08-09 | 2019-02-26 | 科济生物医药(上海)有限公司 | 共表达pd-l1阻断剂的嵌合抗原受体修饰的免疫效应细胞 |
| CN109468279A (zh) | 2017-09-08 | 2019-03-15 | 科济生物医药(上海)有限公司 | 靶向gpc3的免疫效应细胞及其应用 |
| WO2019047932A1 (zh) | 2017-09-08 | 2019-03-14 | 科济生物医药(上海)有限公司 | 基因工程化的t细胞及应用 |
| CN109503715B (zh) | 2017-09-15 | 2023-12-15 | 科济生物医药(上海)有限公司 | Il-4r的融合蛋白及其应用 |
| CN109796532B (zh) | 2017-11-17 | 2024-09-10 | 恺兴生命科技(上海)有限公司 | 靶向成纤维激活蛋白α的结合单元及其应用 |
| CN109880803B (zh) | 2017-12-06 | 2024-06-07 | 恺兴生命科技(上海)有限公司 | 嵌合蛋白、表达嵌合蛋白的免疫效应细胞及其应用 |
| CN110055275A (zh) | 2018-01-19 | 2019-07-26 | 科济生物医药(上海)有限公司 | 一种质粒载体对、其修饰的免疫细胞及其应用 |
| JP2021512875A (ja) | 2018-02-02 | 2021-05-20 | カースゲン セラピューティクス カンパニー リミテッドCarsgen Therapeutics Co., Ltd. | 細胞免疫療法の組み合わせ |
| EP3765094A4 (en) * | 2018-03-15 | 2021-12-22 | KSQ Therapeutics, Inc. | GENE REGULATORY COMPOSITIONS AND PROCEDURES FOR IMPROVED IMMUNOTHERAPY |
| US20220127570A1 (en) | 2018-05-03 | 2022-04-28 | Cafa Therapeutics Limited | Immune effector cell and use thereof |
| CN110438082B (zh) | 2018-05-04 | 2024-03-08 | 恺兴生命科技(上海)有限公司 | 表达il-21r结合蛋白的免疫效应细胞 |
| CN110468105B (zh) | 2018-05-09 | 2024-03-22 | 恺兴生命科技(上海)有限公司 | 表达il-18r结合蛋白的免疫效应细胞 |
| JP2021523743A (ja) | 2018-05-15 | 2021-09-09 | カースゲン セラピューティクス カンパニー リミテッドCarsgen Therapeutics Co., Ltd. | 遺伝子操作された細胞及びその応用 |
| CN112930199B (zh) | 2018-07-24 | 2024-08-13 | 恺兴生命科技(上海)有限公司 | 免疫效应细胞治疗肿瘤的方法 |
| CN112771167B (zh) | 2018-09-20 | 2025-09-26 | 克莱格医学有限公司 | 表达有趋化因子的细胞及用途 |
| AU2019341365A1 (en) | 2018-09-21 | 2021-05-27 | Crage Medical Co., Limited | Method for gene editing of cell on the basis of CRISPR/Cas system |
| US20210347851A1 (en) * | 2018-09-28 | 2021-11-11 | Novartis Ag | Cd19 chimeric antigen receptor (car) and cd22 car combination therapies |
| US12534532B2 (en) | 2018-10-26 | 2026-01-27 | Crage Medical Co., Limited | CLL1-targeting antibody and application thereof |
| EP3892333A4 (en) | 2018-12-07 | 2022-11-30 | CRAGE medical Co., Limited | ANTI-TUMOR POLYIMMUNOTHERAPY |
| JP2022512450A (ja) | 2018-12-13 | 2022-02-03 | カースゲン セラピューティクス カンパニー リミテッド | Gpc3を標的とする免疫エフェクター細胞およびその応用 |
| JP2022523749A (ja) | 2019-02-01 | 2022-04-26 | クレージュ メディカル カンパニー,リミテッド | Tcr融合タンパク質およびtcr融合タンパク質を発現する細胞 |
| US20220325241A1 (en) | 2019-08-09 | 2022-10-13 | Crage Medical Co., Limited | Immune effector cell for co-expressing chemokine receptor |
| CN114867490A (zh) | 2019-09-20 | 2022-08-05 | 克莱格医学有限公司 | 细胞因子调控表达的免疫效应细胞 |
| WO2021057906A1 (zh) | 2019-09-25 | 2021-04-01 | 科济生物医药(上海)有限公司 | 表达il-15的免疫效应细胞 |
| AU2021204861B2 (en) | 2020-01-03 | 2024-10-17 | Crage Medical Co., Limited | Anti-claudin 18.2 antibody and use thereof |
| CN115003818A (zh) | 2020-01-22 | 2022-09-02 | 科济生物医药(上海)有限公司 | 病毒载体转导细胞的方法 |
| KR20230012571A (ko) | 2020-05-18 | 2023-01-26 | 크라제 메디컬 씨오 리미티드 | 면역 이펙터 세포를 이용한 종양 치료 |
-
2022
- 2022-04-08 US US18/284,961 patent/US20240181055A1/en active Pending
- 2022-04-08 EP EP22784155.8A patent/EP4321533A4/en active Pending
- 2022-04-08 JP JP2023562228A patent/JP2024527180A/ja active Pending
- 2022-04-08 WO PCT/CN2022/085921 patent/WO2022214089A1/zh not_active Ceased
- 2022-04-08 CN CN202280022826.0A patent/CN117545771A/zh active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2018508215A (ja) * | 2015-03-05 | 2018-03-29 | ユーシーエル ビジネス ピーエルシー | Cd19結合ドメインを含むキメラ抗原レセプター(car) |
| JP2019515913A (ja) * | 2016-04-22 | 2019-06-13 | 科済生物医薬(上海)有限公司Carsgen Therapeutics Limited | 細胞免疫療法の組成物および方法 |
| JP2019531084A (ja) * | 2016-07-08 | 2019-10-31 | カースゲン セラピューティクス カンパニー リミテッドCarsgen Therapeutics Co., Ltd. | 抗クローディンタンパク質18a2の抗体及びその応用 |
| WO2019170147A1 (zh) * | 2018-03-09 | 2019-09-12 | 科济生物医药(上海)有限公司 | 用于治疗肿瘤的方法和组合物 |
| WO2020143631A1 (zh) * | 2019-01-07 | 2020-07-16 | 科济生物医药(上海)有限公司 | 细胞免疫治疗的组合 |
| CN112062864A (zh) * | 2020-09-18 | 2020-12-11 | 樊克兴 | 靶向bcma肿瘤抗原受体修饰t细胞的制备方法和应用 |
Non-Patent Citations (3)
| Title |
|---|
| JOURNAL OF CLINICAL ONCOLOGY, vol. 37, JPN6026007384, 2019, pages 2759 - 2768, ISSN: 0005808012 * |
| JOURNAL OF CLINICAL ONCOLOGY, vol. 38, JPN6026007385, 2020, pages 3794 - 3804, ISSN: 0005808013 * |
| NATURE MEDICINE, vol. 27, JPN6026007383, March 2021 (2021-03-01), pages 419 - 425, ISSN: 0005808011 * |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022214089A1 (zh) | 2022-10-13 |
| CN117545771A (zh) | 2024-02-09 |
| EP4321533A4 (en) | 2025-05-07 |
| US20240181055A1 (en) | 2024-06-06 |
| EP4321533A1 (en) | 2024-02-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN113286811B (zh) | 改善过继性细胞疗法的效力和安全性 | |
| US11786555B2 (en) | RAR selective agonists in combination with immune modulators for cancer immunotherapy | |
| US20240325450A1 (en) | Nkt-cell subset for in vivo persistence and therapeutic activity and propagation of same | |
| US20250177544A1 (en) | Method and composition for treating tumors | |
| CN111629734A (zh) | 用于共刺激的新型平台、新型car设计以及过继性细胞疗法的其他增强 | |
| KR20230016183A (ko) | 키메라 항원 수용체를 발현하는 바이러스 특이적 면역 세포 | |
| KR20190101979A (ko) | 합성 면역 수용체 및 이의 사용 방법 | |
| KR20210110811A (ko) | 입양 세포 요법에서 b 세포 악성 종양의 투약 및 치료 방법 | |
| CN114206357A (zh) | 使用融合蛋白进行tcr重编程的组合物和方法 | |
| JP2023528632A (ja) | Cd30陽性癌の処置 | |
| US20240181055A1 (en) | Cellular immunotherapy use | |
| TW202328438A (zh) | 淋巴瘤之治療 | |
| US20240209058A1 (en) | Mesothelin-specific T cell Receptors and Methods of Using Same | |
| WO2018148180A2 (en) | Materials and methods for identifying and treating cancer patients | |
| WO2026075949A1 (en) | Death receptor 5-targeted chimeric antigen receptors and uses thereof | |
| WO2022268162A1 (zh) | 治疗肿瘤的方法和组合物 | |
| Van den Eynde | O16 Immunoscore® Colon analytical performance | |
| Donia et al. | Partially differentiated polyfunctional T cells dominate the periphery after tumor-infiltrating lymphocytes therapy for cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20250314 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20250314 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20260218 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20260303 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20260527 |